Evox Therapeutics is a private biotechnology company founded in 2016 and headquartered in Oxford, United Kingdom. The company specializes in developing exosome-based therapeutics using its proprietary DeliverEX™ platform technology. Evox Therapeutics operates under the leadership of CEO Dr. Antonin de Fougerolles and has secured significant funding through Series B rounds and strategic partnerships, positioning itself as a leader in extracellular vesicle-based drug delivery for neurological applications. The company's strategic focus addresses a critical challenge in neurodegenerative disease treatment: delivering therapeutic agents across the blood-brain barrier to the central nervous system.
Function/Biology
Evox Therapeutics leverages naturally occurring extracellular vesicles, particularly exosomes, as delivery vehicles for therapeutic cargo. Exosomes are 30-150 nanometer diameter membrane-bound particles secreted by cells containing proteins, lipids, and nucleic acids including microRNAs and messenger RNA. The DeliverEX™ platform technology represents an engineered approach to loading specific therapeutic molecules into exosomes and directing them to target tissues, particularly the brain and spinal cord.
...
Evox Therapeutics
Overview
Evox Therapeutics is a private biotechnology company founded in 2016 and headquartered in Oxford, United Kingdom. The company specializes in developing exosome-based therapeutics using its proprietary DeliverEX™ platform technology. Evox Therapeutics operates under the leadership of CEO Dr. Antonin de Fougerolles and has secured significant funding through Series B rounds and strategic partnerships, positioning itself as a leader in extracellular vesicle-based drug delivery for neurological applications. The company's strategic focus addresses a critical challenge in neurodegenerative disease treatment: delivering therapeutic agents across the blood-brain barrier to the central nervous system.
Function/Biology
Evox Therapeutics leverages naturally occurring extracellular vesicles, particularly exosomes, as delivery vehicles for therapeutic cargo. Exosomes are 30-150 nanometer diameter membrane-bound particles secreted by cells containing proteins, lipids, and nucleic acids including microRNAs and messenger RNA. The DeliverEX™ platform technology represents an engineered approach to loading specific therapeutic molecules into exosomes and directing them to target tissues, particularly the brain and spinal cord.
The company's approach involves engineering exosomes derived from various cell types to carry therapeutic payloads such as RNA therapeutics (small interfering RNAs and antisense oligonucleotides) and proteins. This biological delivery system exploits the exosome's natural ability to cross cellular membranes and penetrate the blood-brain barrier, a significant advantage over many conventional delivery methods. The surface of exosomes can be modified to include targeting ligands that direct the vesicles to specific cell types or brain regions affected by neurodegeneration.
Role in Neurodegeneration
Evox Therapeutics directly addresses multiple neurodegenerative conditions through its therapeutic pipeline. The company's development programs include candidates targeting Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). These conditions share a common challenge: delivering disease-modifying agents to affected neurons in the central nervous system while overcoming the selective permeability of the blood-brain barrier.
The exosome-based approach offers particular advantages for neurodegenerative disease treatment. Unlike small molecules that may accumulate systemically or large biologics that cannot efficiently cross the blood-brain barrier, exosomes represent a biomimetic solution that leverages endogenous cellular communication pathways. This enables delivery of RNA therapeutics capable of modulating disease-related gene expression in neurons and glial cells, potentially addressing pathogenic processes underlying neurodegeneration.
Molecular Mechanisms
The DeliverEX™ platform operates through engineered modification of exosome biogenesis and cargo loading. The technology involves manipulating cellular machinery responsible for exosome formation, allowing controlled loading of therapeutic RNA or proteins into vesicles destined for secretion. This requires modulation of the endosomal sorting complex required for transport (ESCRT) machinery and tetraspanin proteins that regulate exosome formation and content.
Surface engineering of exosomes typically involves displaying targeting peptides or antibody fragments derived from proteins naturally expressed on exosome surfaces. These modifications guide exosomes to cells expressing complementary receptors, including those involved in receptor-mediated endocytosis. Upon cellular uptake, therapeutic cargo is released into the cytoplasm or targeted to specific cellular compartments where it exerts therapeutic effects.
For neurodegeneration applications, Evox's candidates targeting tau pathology or alpha-synuclein aggregation likely utilize antisense oligonucleotides or small interfering RNAs that reduce expression of these disease-associated proteins. Alternative approaches employ exosomes carrying neuroprotective proteins or gene-editing machinery to address genetic mutations underlying familial neurodegenerative diseases.
Clinical/Research Significance
Evox Therapeutics represents an emerging class of therapeutic developers addressing a fundamental challenge in neurology: effective blood-brain barrier penetration. The company's approach potentially enables previously undruggable central nervous system targets to be therapeutically modulated. Success in clinical development would establish exosome-based delivery as a validated platform for neurodegeneration treatment, potentially accelerating development of numerous RNA and protein therapeutics currently restricted by delivery limitations.